Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Cyclophosphamide 4Vincristine 2selinexor 1fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1apatinib 1VAP-cyclo protocol 1Thiotepa 1Rituximab 1Radiotherapy 1R-CHOP protocol 1Prednisone 1Nurse Clinicians 1Methotrexate 1Melphalan 1Lomustine 1Ifosfamide 1Idarubicin 1Filgrastim 1Etoposide 1Epirubicin 1Doxorubicin 1Dexamethasone 1Decitabine 1Cytarabine 1Carmustine 1Brentuximab Vedotin 1Blood Pressure 1Antiretroviral Therapy, Highly Active 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Large B-Cell, Diffuse × apatinib × Clear all
NCT03376958 2019-07-25

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Zhengzhou University

Phase 4 Completed
32 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡